Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : EVO101
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : EQT Life Sciences
Deal Size : $50.0 million
Deal Type : Series B Financing
Arix Co-leads $50 Million Series B Financing for New Portfolio Company Evommune
Details : The capital raised will support Evommune’s three prioritised pipeline programs targeting highly prevalent inflammatory diseases, including EVO101, a novel small molecule inhibitor of the IRAK4.
Product Name : EVO101
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 27, 2023
Lead Product(s) : EVO101
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : EQT Life Sciences
Deal Size : $50.0 million
Deal Type : Series B Financing